Yihua Zhang, Yuna Shao, Liying Zhang, Shihang Ren, Di Lu, Huiling Zhang et al. Repurposing cadazolid as a CBLB-dependent non-PROTAC FAK degrader to suppress lung adenocarcinoma and restore EGFR-TKI sensitivity. // Journal of Pharmaceutical Analysis. – 2026. – DOI: 10.1016/j.jpha.2026.101839. – URL: https://doi.org/10.1016/j.jpha.2026.101839
Yihua Zhang, Yuna Shao, Liying Zhang, Shihang Ren, Di Lu, Huiling Zhang, Xinyu Qian, Yuling Chen, Yang Yang, Jianjie Zhu, Yuanyuan Zeng, Shengjie Wang, Zhaowei Yan, & Zeyi Liu (2026). Repurposing cadazolid as a CBLB-dependent non-PROTAC FAK degrader to suppress lung adenocarcinoma and restore EGFR-TKI sensitivity. Journal of Pharmaceutical Analysis. https://doi.org/10.1016/j.jpha.2026.101839
Yihua Zhang, et al. “Repurposing cadazolid as a CBLB-dependent non-PROTAC FAK degrader to suppress lung adenocarcinoma and restore EGFR-TKI sensitivity.” Journal of Pharmaceutical Analysis, 2026. doi:10.1016/j.jpha.2026.101839.
@article{Zhang2026,
title = {Repurposing cadazolid as a CBLB-dependent non-PROTAC FAK degrader to suppress lung adenocarcinoma and restore EGFR-TKI sensitivity},
author = {Zhang, Yihua and Shao, Yuna and Zhang, Liying and Ren, Shihang and Lu, Di and Zhang, Huiling and Qian, Xinyu and Chen, Yuling and Yang, Yang and Zhu, Jianjie and Zeng, Yuanyuan and Wang, Shengjie and Yan, Zhaowei and Liu, Zeyi},
journal = {Journal of Pharmaceutical Analysis},
year = {2026},
doi = {10.1016/j.jpha.2026.101839},
url = {https://doi.org/10.1016/j.jpha.2026.101839}
}